Matrixyl
Palmitoyl Pentapeptide-4 (pal-KTTKS)
Palmitoyl pentapeptide-4 is a signal peptide that mimics a collagen I degradation fragment (matrikine) to stimulate fibroblast collagen synthesis; a 12-week RCT (N=93) showed statistically significant wrinkle reduction versus placebo, though the evidence base remains largely manufacturer-linked rather than drug-grade (EXA-bb059b10b8a5, citing Robinson et al. 2005, Int J Cosmet Sci; PMID 23320752; PMID 27877059).
Last updated: 2026-03-09
Safety Summary
Matrixyl has a favorable safety profile with over 20 years of commercial use. The CIR assessed palmitoyl pentapeptide-4 as safe in cosmetic formulations. The EWG gives it a safety score of 1 (very safe). Robinson et al. (2005) reported good tolerability across all skin types in their 93-subject RCT. No serious adverse effects have been reported in the literature. Minor skin irritation is possible at very high concentrations, but Matrixyl is effective at extremely low concentrations (as low as 3 ppm), minimizing risk. Suitable for sensitive skin. However, systematic human safety reporting is limited -- the FDA FAERS database contains no adverse event reports for Matrixyl, which reflects absence of drug-level monitoring rather than proof of long-term safety (PMID 39858482).
Known Side Effects
rare
rare
Who Should NOT Use This
Standard precaution for any topical product. No specific contraindications identified in source literature. Patch testing recommended for individuals with known peptide sensitivities.
Peptides are unstable at low pH and can be hydrolyzed by strong acids. Apply at different times of day rather than layering directly. Baumann explicitly advises against using peptides before a vitamin C serum.
Talk to Your Doctor
Before considering Matrixyl, discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-11]
Evidence Assessment
Tier 3: Multiple smaller human clinical studies exist but no large independent Phase 3-style trials. The Robinson et al. (2005) RCT (N=93, 12 weeks, double-blind, placebo-controlled, split-face) is the most rigorous, showing statistically significant wrinkle reduction (EXA-bb059b10b8a5). Lintner (2005) showed 18% fold depth reduction and 21% firmness improvement in a 28-day study (EXA-bb059b10b8a5). Aruan et al. (2023) conducted an 8-week double-blind RCT (N=21) favoring Matrixyl over Argireline and placebo (EXA-bb059b10b8a5). In vitro data is strong, with concentration-dependent collagen stimulation confirmed in human fibroblasts (PMID 23320752). However, most clinical studies are manufacturer-sponsored (Sederma), sample sizes are modest, and independent large-scale RCTs are lacking. Human evidence is not drug-grade -- the studies are cosmetic-context trials, not pharmaceutical development (PMID 27877059; PMID 33195061). This is a cosmetic ingredient, not a pharmaceutical drug, so no Phase 2/3 drug trials exist. The evidence base exceeds Tier 4 (animal/in vitro only) since multiple human studies with positive results exist, but does not reach Tier 2 (Phase 3 RCT data).
1Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin
Robinson LR et al. - International Journal of Cosmetic Science (2005) - RCT (double-blind, placebo-controlled, split-face) - N=93 women
12-week study. Expert graders and quantitative image analysis confirmed statistically significant reductions in fine lines and wrinkles versus placebo. Well-tolerated across all skin types. Effective at very low concentrations. Some analyses noted small effect sizes with not all parameters reaching statistical significance.
Limitations: Manufacturer-sponsored study (Sederma/P&G). Effect sizes described as small by some reviewers. Baumann described the improvement as statistically insignificant across all parameters (EXA-f2d51930ebc7).
2Promoting production in the extracellular matrix without promoting inflammation
Lintner K - Cosmetics & Toiletries (2005) - Clinical study (double-blind) - Not specified in available data
28-day study with 0.005% palmitoyl pentapeptide-4 cream applied twice daily to periorbital area. Reported 18% decrease in fold depth, 37% reduction in fold thickness, and 21% improvement in skin firmness.
Limitations: Manufacturer-sponsored (Sederma). Short duration (28 days). Sample size not available in source data. Published in trade journal, not peer-reviewed journal.
3Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet
Aruan et al. - PMC / ResearchGate (2023) - RCT (double-blind, randomized) - N=21 Indonesian women
8-week comparison of palmitoyl pentapeptide-4 vs Argireline vs placebo for crow's feet. Palmitoyl pentapeptide-4 outperformed both Argireline and placebo based on clinical photos, data measurements, and self-assessment questionnaires.
Limitations: Small sample size (N=21). Single ethnic group (Indonesian women). Short to moderate duration.
4Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblastsPMID 23320752
Jones RR et al. - Molecular Pharmaceutics (2013) - In vitro - Human dermal and corneal fibroblast cultures
C16-KTTKS stimulates collagen production in a concentration-dependent manner close to the critical aggregation concentration. Self-assembly into nanotape structures and collagen stimulation appear to be interrelated.
Limitations: In vitro study only. Cell culture conditions do not replicate the skin penetration barrier. Results may not translate directly to topical application in vivo.
5Synergistic Effects of Injectable Platelet-Rich Fibrin and Bioactive Peptides on Dermal Fibroblast Viability and Extracellular Matrix Gene Expression: An In Vitro StudyPMID 40871567
Paccola AGL et al. - Molecules (Basel, Switzerland) (2025) - In vitro - Human dermal fibroblast cultures (6 conditions)
Combinations of iPRF + Matrixyl and iPRF + GEKG led to increased cell viability and upregulated ECM-related genes (COL1A1, FN1, HAS1) at 72h. Effects were stronger than individual treatments, suggesting synergistic effects. Synergistic effects were stronger with GEKG than Matrixyl.
Limitations: In vitro study only. Combination design makes Matrixyl-specific inference limited. Does not address skin penetration.
6Skin rejuvenation using cosmetic products containing growth factors, cytokines, and matrikines: a review of the literaturePMID 27877059
Aldag C et al. - Clinical, Cosmetic and Investigational Dermatology (2016) - Review - Literature review
Reviews commercially available matrikine-containing products. Notes that matrikines offer growth factor-like activities with better skin penetration due to smaller molecular size. Supports the role of matrikines in skin rejuvenation.
Limitations: Narrative review. Does not include original clinical data.
7Cosmeceutical Peptides in the Framework of Sustainable Wellness EconomyPMID 33195061
Errante F et al. - Frontiers in Chemistry (2020) - Review - Literature review
Reviews signal peptides, carrier peptides, and neurotransmitter inhibitors for cosmetic use. Discusses Matrixyl among the most investigated cosmeceutical peptides. Notes that scientific studies supporting claimed biological activity should underpin the cosmeceutical field.
Limitations: Review article. Notes that the evidence base is not fully mature. DOI may not match this specific paper (potential metadata error in source data).
8Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A ReviewPMID 39858482
Pintea A et al. - Biomolecules (2025) - Review - Literature review
Reviews signal peptides including Matrixyl. Discusses poor permeability through membranes as a key limitation. Reviews physical methods (microneedling, iontophoresis) and nano-delivery systems to improve peptide bioavailability.
Limitations: Review article. Highlights the delivery problem as a fundamental challenge for all cosmetic peptides. DOI may not match this specific paper (potential metadata error in source data).
9Self-Assembly, Tunable Hydrogel Properties, and Selective Anti-Cancer Activity of a Carnosine-Derived Lipidated PeptidePMID 31407889
Castelletto V et al. - ACS Applied Materials & Interfaces (2019) - In vitro (basic science) - Cell culture (MCF-7 breast cancer + fibroblast controls)
A novel lipopeptide C16KTTbetaAH was designed incorporating the KTT tripeptide from Matrixyl. Showed selective concentration-dependent cytotoxicity against MCF-7 cancer cells. The cytotoxicity was below the critical aggregation concentration.
Limitations: Basic science / materials study. The cancer selectivity finding is preliminary and in vitro only. Not directly about Matrixyl's cosmetic use.
10Cosmeceuticals: the new medicine of beautyPMID 21462614
Martin KI, Glaser DA - Missouri Medicine (2011) - Review - Literature review
Reviews cosmeceuticals as products between cosmetics and pharmaceuticals. Discusses active ingredients including peptides. Notes growing patient interest and the importance of physicians understanding benefits, limitations, and potential adverse effects.
Limitations: General review, not Matrixyl-specific. Published in a regional medical journal.
11Cosmetic Peptide Efficacy: Clinical Trial Evidence
PeptideJournal editorial - PeptideJournal (2025) - Secondary evidence review - Summarizes multiple small Matrixyl topical trials including the 93-woman 12-week trial, 28-day, and 8-week studies
Reports that small topical studies found wrinkle-related improvements for palmitoyl pentapeptide-4. Notes signal peptides had strongest wrinkle depth reduction (SMD = -0.85) in a 2025 meta-analysis of 16 RCTs (Al-Harbi et al. 2025). Notes evidence base is small and frequently industry-linked.
Limitations: Secondary source, not primary trial publication. Underlying trials are summarized but not fully reported. The 2025 meta-analysis is cited from ResearchGate and may not yet be peer-reviewed.